Litigation Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2019)
✉ Email this page to a colleague
CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-02-08 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-02-21 |
| Cause | Assigned To | Susan Davis Wigenton | |
| Jury Demand | Referred To | Cathy L. Waldor | |
| Patents | 10,166,242; 10,166,243; 10,195,214; 9,943,526 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-02-07 | 1 | Complaint | United States Patent Nos. 10,166,242 (“the ʼ242 patent”), 10,166,243 (“the ʼ243 patent”), and 10,195,214… This complaint is an action for patent infringement under the patent laws of the United States, 35 U.S.C…10,195,214 (“the ʼ214 patent”) (together, “the patents-in-suit”), owned by Corcept. … 1 The ʼ242 patent is a continuation of U.S. Patent No. 9,943,526, which has been asserted… 2 The ʼ243 patent is a continuation of the ʼ242 patent. | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
